近日，微医控股凭借在数字健康领域的系统性创新和AI医疗垂直领域的卓越实践，连获两项权威殊 荣：蓝鲸新闻2025鲸潮奖"年度创新领航企业"和格隆汇金格奖"年度卓越人工智能应用企业"。 作为国际领先的AI医疗平台，微医控股创新建设运营"AI健共体"，构建了"按健康结果付费"的服务模 式，成功推动"价值医疗"实现规模化落地。该模式不仅帮助超百万用户实现健康指标改善，更形成了清 晰的商业化路径，为行业提供了从技术突破到产业赋能的系统性解决方案。 AI健共体驱动价值医疗，获评"年度创新领航企业" 12月22日，在格隆汇"金格奖"年度卓越公司评选中，微医控股获评"年度卓越人工智能应用企业"。该奖 项旨在表彰在人工智能领域实现技术突破、指引未来发展路径的领先公司。 格隆汇指出，获奖企业成功将AI技术应用到新的或现有场景中，创造出显著的商业与社会价值。微医 控股依托"AI健共体"提供健康管理会员服务，截至2025年6月30日，该服务已覆盖约110万名健康会员， 形成"健康会员制+高附加值服务"的成熟体系。2025年上半年，公司AI医疗服务收入达28.41亿元，同比 增长97.3%，展现出强劲的商业成长性。 基于自研医疗大模型 ...

Group 1 - The annual Cloud Summit held in Hangzhou showcased advancements in AI technology and its applications in healthcare, with a focus on the integration of AI in medical services [1][2] - Micro Medical Holdings presented its AI-driven healthcare solutions, including the "Micro Medical AI General Hospital" and the AI health assistant "Micro Xiao Yi," which attracted significant attention [1][2] - The forum titled "AI Agent Defines Future Life: Evolving from 'Tool' to 'Digital Partner'" featured a keynote speech by Xu Hongxia, emphasizing how AI is reshaping healthcare services and management [1][2] Group 2 - AI technology is addressing structural challenges in China's healthcare system, such as uneven resource distribution and high chronic disease prevalence, by shifting the focus from "treatment-centered" to "health-centered" care [2][3] - The Tianjin AI Health Community, driven by the Micro Medical AI General Hospital, has seen significant improvements in outpatient volume and reduced average costs, alongside enhanced health metrics for diabetes management [2][3] - The AI-driven healthcare model has achieved a "two increases and one decrease" outcome, benefiting patients, healthcare providers, and insurance funds [3] Group 3 - The Micro Medical AI General Hospital has developed various AI agents, including AI doctors and AI pharmacists, to enhance the entire medical service process from pre-diagnosis to post-treatment [3][5] - The AI doctor has improved the quality of care in grassroots healthcare settings, achieving a 99.97% compliance rate for reminders on inappropriate prescriptions, thereby enhancing medical safety [3][5] Group 4 - The Micro Medical large model integrates clinical data and decision-making pathways, establishing a robust foundation for health-centered value-based care [5] - The model includes over 13,000 specialized medical rules and 222,000 medication review rules, ensuring evidence-based compliance in AI decision-making processes [5] Group 5 - The "Micro Xiao Yi" health management product offers personalized health monitoring and management services, utilizing user health profiles and wearable devices to create a closed-loop service [6][9] - The product provides real-time health advice and connects users to medical services, enhancing the overall healthcare experience [6][9] - "Micro Xiao Yi" is positioned as the first clinical-grade AI health assistant covering the entire medical process, aiming to improve health management and patient engagement [9]